logo
Plus   Neg
Share
Email

Ameren Q2 Profit Tops View, But Revenues Miss

Ameren Corp. (AEE) second quarter 2020 net income attributable to common shareholders of $243 million or $0.98 per share, up from $179 million or $0.72 per share in the second quarter 2019. Analysts polled by Thomson Reuters expected the company to report earnings of $0.87 per share for the quarter. Analysts' estimates typically exclude special items.

The second quarter 2020 results reflected earnings on increased infrastructure investments made across all business segments driven by solid execution of the company's strategy.

The earnings improvement also resulted from lower Ameren Missouri operations and maintenance expenses due to the absence of a refueling and maintenance outage at the Callaway Energy Center compared to the year-ago period when there was such an outage, as well as disciplined cost management.

Total operating revenues for the quarter grew to $1.40 billion from $1.38 billion in the prior year. Analysts expected revenue of $1.44 billion for the quarter.

Ameren reaffirmed its 2020 earnings guidance range of $3.40 to $3.60 per share. Analysts expect annual earnings of $3.45 per share.

AEE closed Thursday regular trading at $81.06 up $0.61 or 0.76 percent. But in the after-hours, the stock dropped $10.81 or 13.34 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
RELATED NEWS
Follow RTT